Moderna (MRNA) Announces Phase 1/2 Data on mRNA-3927
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
May 3, 2023 4:06 PM EDTAfter completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to determine a recommended dose
CAMBRIDGE, MA / ACCESSWIRE / May 3, 2023 / Moderna,Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that an abstract reporting on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA) has been accepted for presentation at the 2023 American Society of Gene + Cell... More
